AD

AdvanCell

Cambridge, US · Founded 2026 · Delaware corporation · 7 known investors

advancell.com.au ↗

AdvanCell develops radioisotope-based therapies, using Th-228 sourced through the U.S. Department of Energy Isotope Program via the National Isotope Development Center. The company operates in the radiopharmaceutical and biotech space, focused on isotopes for medical applications.

Investors · 7

BA

Bain Capital Life SciencesBoston

CA

Catalio Capital Management, LPNew York

PR

Proto AxiomSydney

SV

SV Health InvestorsBoston · $1M – $20M

TE

Tenmile

AB

AbingworthreportedLondon · $15M – $30Mvia Bali Muralidhar · board

SA

Sanofi VenturesreportedCambridge · $5M

Reported raises · per SEC filings

Form D private placements

▶$218.3MraisedJul 2026 · 41 investors · Biotechnology

Rule 506(b)

AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360intelligence360.news · Aug 2026AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructurebusinesswire.com · Jul 2026 · press release

Officers, directors & promoters on the filing

• Philina LeeExecutive Officer, Director
• Aaron PickettExecutive Officer
• Wing Cheong LamDirector
• Nik EconomopoulosDirector
• Anthony AiudiDirector
• Bali MuralidharDirector
• Jamil BegDirector
• Christopher GagliardiDirector
• Andrew AdamovichDirector
• Andrew KayDirector
• Kevin CameronDirector

Offering amount

$315M

Amount sold

$218.3M

First sale

Jun 2026

Incorporated

Corporation, Delaware, 2026

Federal exemptions

06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.